AC Immune
ACIU
43 hedge funds and large institutions have $107M invested in AC Immune in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 19 reducing their positions, and 7 closing their positions.
230% more call options, than puts
Call options by funds: $783K | Put options by funds: $237K
0.51% less ownership
Funds ownership: 28.8% → 28.29% (-0.51%)
4% less funds holding
Funds holding: 45 → 43 (-2)
7% less capital invested
Capital invested by funds: $114M → $107M (-$7.42M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
53% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$347K |
| 3 |
BlackRock
New York
|
+$234K |
| 4 |
Millennium Management
New York
|
+$209K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.29M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$754K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$396K |
| 4 |
Two Sigma Investments
New York
|
-$147K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$141K |
ACIU Hedge Fund Activity: Q3 2024 in Review
43 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q3 2024, worth a combined $107M — down 6.5% from $114M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ACIU and 5 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 9 added.
The largest buyer was BVF Inc, adding an estimated $2.4M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.29M sold.
- 43 institutional investors held AC Immune (ACIU) as of Q3 2024, down from 45 in Q2 2024.
- Funds reported $107M of AC Immune stock for Q3 2024, down 6.5% quarter-over-quarter.
- 5 funds opened new AC Immune positions in Q3 2024 and 7 closed out, a net change of -2 holders.
- The largest AC Immune buyer in Q3 2024 was BVF Inc, an estimated $2.4M added.
- The largest AC Immune seller in Q3 2024 was Avidity Partners Management, an estimated $3.29M sold.
Based on aggregated 13F filings for Q3 2024.